Stockholders of Ventyx Biosciences, Inc. approved the Agreement and Plan of Merger with Eli Lilly and Company at a special meeting held virtually on March 3, 2026. The merger agreement was approved with 44,176,785 votes For, 1,572,592 Against, and 61,369 Abstain. Stockholders also approved, on a non-binding advisory basis, the compensation that will or may become payable to named executive officers in connection with the Merger, with 43,789,693 votes For, 1,838,898 Against, and 182,155 Abstain. As of the January 21, 2026 record date, 71,760,778 common shares were issued and outstanding, with 45,810,746 shares represented at the Special Meeting.